Is preclinical autoimmunity benign? The case of cardiovascular disease

Darcy S. Majka*, Rowland W. Chang

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Although there are many examples of autoantibodies in disease-free individuals, they can be a preclinical phenomenon heralding future autoimmune rheumatic disease. They may be a marker for autoreactive B-cell activation and other inflammatory autoimmune processes. The increased prevalence of cardiovascular disease (CVD) in autoimmune rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, and the increased risk of CVD in patients with rheumatic disease with autoantibodies, suggest that CVD may have autoimmune features. Autoantibodies might be risk markers for subclinical and clinical CVD development not only in patients with rheumatic diseases but in the general population as well.

Original languageEnglish (US)
Pages (from-to)659-668
Number of pages10
JournalRheumatic Disease Clinics of North America
Issue number4
StatePublished - Nov 1 2014


  • Autoantibodies
  • Autoimmunity
  • Cardiovascular disease
  • Coronary artery calcification
  • Intima media thickness
  • Preclinical

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Is preclinical autoimmunity benign? The case of cardiovascular disease'. Together they form a unique fingerprint.

Cite this